430 related articles for article (PubMed ID: 17440083)
1. Syndecan-2 affects the basal and chemotherapy-induced apoptosis in osteosarcoma.
Orosco A; Fromigué O; Bazille C; Entz-Werle N; Levillain P; Marie PJ; Modrowski D
Cancer Res; 2007 Apr; 67(8):3708-15. PubMed ID: 17440083
[TBL] [Abstract][Full Text] [Related]
2. High Wnt signaling represses the proapoptotic proteoglycan syndecan-2 in osteosarcoma cells.
Dieudonné FX; Marion A; Haÿ E; Marie PJ; Modrowski D
Cancer Res; 2010 Jul; 70(13):5399-408. PubMed ID: 20530678
[TBL] [Abstract][Full Text] [Related]
3. Anticancer agents sensitize osteosarcoma cells to TNF-related apoptosis-inducing ligand downmodulating IAP family proteins.
Mirandola P; Sponzilli I; Gobbi G; Marmiroli S; Rinaldi L; Binazzi R; Piccari GG; Ramazzotti G; Gaboardi GC; Cocco L; Vitale M
Int J Oncol; 2006 Jan; 28(1):127-33. PubMed ID: 16327988
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells.
Castro-Gamero AM; Borges KS; da Silva Silveira V; Lira RC; de Paula Gomes Queiroz R; Valera FC; Scrideli CA; Umezawa K; Tone LG
Anticancer Drugs; 2012 Jul; 23(6):638-50. PubMed ID: 22382389
[TBL] [Abstract][Full Text] [Related]
5. Statin-induced inhibition of 3-hydroxy-3-methyl glutaryl coenzyme a reductase sensitizes human osteosarcoma cells to anticancer drugs.
Fromigué O; Hamidouche Z; Marie PJ
J Pharmacol Exp Ther; 2008 May; 325(2):595-600. PubMed ID: 18252811
[TBL] [Abstract][Full Text] [Related]
6. E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents.
Russo AJ; Magro PG; Hu Z; Li WW; Peters R; Mandola J; Banerjee D; Bertino JR
Cancer Res; 2006 Jul; 66(14):7253-60. PubMed ID: 16849574
[TBL] [Abstract][Full Text] [Related]
7. Calpain-6 is an endothelin-1 signaling dependent protective factor in chemoresistant osteosarcoma.
Marion A; Dieudonné FX; Patiño-Garcia A; Lecanda F; Marie PJ; Modrowski D
Int J Cancer; 2012 Jun; 130(11):2514-25. PubMed ID: 21681744
[TBL] [Abstract][Full Text] [Related]
8. Induction of apoptosis in osteogenic sarcoma cells by combination of tumor necrosis factor-related apoptosis inducing ligand and chemotherapeutic agents.
Sun J; Fu ZM; Fang CQ; Li JH
Chin Med J (Engl); 2007 Mar; 120(5):400-4. PubMed ID: 17376311
[TBL] [Abstract][Full Text] [Related]
9. Sensitization of osteosarcoma cell line SaOS-2 to chemotherapy by downregulating survivin.
Zou J; Gan M; Mao N; Zhu X; Shi Q; Yang H
Arch Med Res; 2010 Apr; 41(3):162-9. PubMed ID: 20682173
[TBL] [Abstract][Full Text] [Related]
10. Profiling of chemonaive osteosarcoma and paired-normal cells identifies EBF2 as a mediator of osteoprotegerin inhibition to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Patiño-García A; Zalacain M; Folio C; Zandueta C; Sierrasesúmaga L; San Julián M; Toledo G; De Las Rivas J; Lecanda F
Clin Cancer Res; 2009 Aug; 15(16):5082-91. PubMed ID: 19671856
[TBL] [Abstract][Full Text] [Related]
11. Dual involvement of protein kinase C delta in apoptosis induced by syndecan-2 in osteoblasts.
Orosco A; Fromigué O; Haÿ E; Marie PJ; Modrowski D
J Cell Biochem; 2006 Jul; 98(4):838-50. PubMed ID: 16440330
[TBL] [Abstract][Full Text] [Related]
12. Targeted inhibition of T-cell factor activity promotes syndecan-2 expression and sensitization to doxorubicin in osteosarcoma cells and bone tumors in mice.
Dieudonné FX; Marion A; Marie PJ; Modrowski D
J Bone Miner Res; 2012 Oct; 27(10):2118-29. PubMed ID: 22550000
[TBL] [Abstract][Full Text] [Related]
13. Syndecan-2 overexpression induces osteosarcoma cell apoptosis: Implication of syndecan-2 cytoplasmic domain and JNK signaling.
Modrowski D; Orosco A; Thévenard J; Fromigué O; Marie PJ
Bone; 2005 Aug; 37(2):180-9. PubMed ID: 15936998
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide.
Bruheim S; Xi Y; Ju J; Fodstad O
Clin Cancer Res; 2009 Dec; 15(23):7161-9. PubMed ID: 19920113
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines.
Murayama T; Kawasoe Y; Yamashita Y; Ueno Y; Minami S; Yokouchi M; Komiya S
Anticancer Res; 2008; 28(4B):2147-54. PubMed ID: 18751388
[TBL] [Abstract][Full Text] [Related]
16. 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients.
Pasello M; Hattinger CM; Stoico G; Manara MC; Benini S; Geroni C; Mercuri M; Scotlandi K; Picci P; Serra M
Eur J Cancer; 2005 Sep; 41(14):2184-95. PubMed ID: 16140527
[TBL] [Abstract][Full Text] [Related]
17. Mevalonate pathway inhibitors affect anticancer drug-induced cell death and DNA damage response of human sarcoma cells.
Nilsson S; Huelsenbeck J; Fritz G
Cancer Lett; 2011 May; 304(1):60-9. PubMed ID: 21356574
[TBL] [Abstract][Full Text] [Related]
18. Id3-mediated enhancement of cisplatin-induced apoptosis in a sarcoma cell line MG-63.
Koyama T; Suzuki H; Imakiire A; Yanase N; Hata K; Mizuguchi J
Anticancer Res; 2004; 24(3a):1519-24. PubMed ID: 15274318
[TBL] [Abstract][Full Text] [Related]
19. Syndecan-2 overexpression regulates adhesion and migration through cooperation with integrin alpha2.
Choi S; Kim Y; Park H; Han IO; Chung E; Lee SY; Kim YB; Lee JW; Oh ES; Yi JY
Biochem Biophys Res Commun; 2009 Jun; 384(2):231-5. PubMed ID: 19394307
[TBL] [Abstract][Full Text] [Related]
20. Effect of human granulocyte macrophage-colony stimulating factor on differentiation and apoptosis of the human osteosarcoma cell line SaOS-2.
Postiglione L; Di Domenico G; Giordano-Lanza G; Ladogana P; Turano M; Castaldo C; Di Meglio F; Cocozza S; Montagnani S
Eur J Histochem; 2003; 47(4):309-16. PubMed ID: 14706926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
